BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
76 hedge funds and large institutions have $70M invested in BRAINSTORM CELL THERAPUTC in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 8 closing their positions.
313% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 8
307% more capital invested
Capital invested by funds: $17.2M → $70M (+$52.8M)
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
49% more funds holding
Funds holding: 51 → 76 (+25)
0.51% more ownership
Funds ownership: 0.9% → 1.41% (+0.51%)
76% less call options, than puts
Call options by funds: $9.36M | Put options by funds: $38.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.04M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.61M |
| 4 |
AHB
Abner Herrman & Brock
Jersey City,
New Jersey
|
+$1.31M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.13M |
| 2 |
Millennium Management
New York
|
-$1.32M |
| 3 |
JP Morgan Chase
New York
|
-$460K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$346K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$100K |
BCLI Hedge Fund Activity: Q2 2020 in Review
76 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2020, worth a combined $70M — up 307% from $17.2M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new BCLI positions and 8 closed out — a net gain of 25 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $10.6M. The largest seller was Renaissance Technologies, cutting an estimated $3.13M.
- 76 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2020, up from 51 in Q1 2020.
- Funds reported $70M of BRAINSTORM CELL THERAPUTC stock for Q2 2020, up 307% quarter-over-quarter.
- 33 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2020 and 8 closed out, a net change of +25 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2020 was BlackRock, an estimated $10.6M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2020 was Renaissance Technologies, an estimated $3.13M sold.
Based on aggregated 13F filings for Q2 2020.